SG11201704829QA - Methods and compositions for treating brain diseases - Google Patents

Methods and compositions for treating brain diseases

Info

Publication number
SG11201704829QA
SG11201704829QA SG11201704829QA SG11201704829QA SG11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
brain diseases
treating brain
treating
Prior art date
Application number
SG11201704829QA
Other languages
English (en)
Inventor
Beverly L Davidson
John H Lee
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of SG11201704829QA publication Critical patent/SG11201704829QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002Small monomeric GTPase (3.6.5.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11201704829QA 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases SG11201704829QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098085P 2014-12-30 2014-12-30
PCT/US2015/068034 WO2016109649A1 (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Publications (1)

Publication Number Publication Date
SG11201704829QA true SG11201704829QA (en) 2017-07-28

Family

ID=56285031

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704829QA SG11201704829QA (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Country Status (12)

Country Link
US (1) US11612641B2 (https=)
EP (1) EP3240577B1 (https=)
JP (1) JP6782701B2 (https=)
KR (1) KR102618947B1 (https=)
CN (1) CN107405414A (https=)
AU (1) AU2015374043B2 (https=)
BR (1) BR112017013674A2 (https=)
CA (1) CA2971687C (https=)
ES (1) ES2962439T3 (https=)
SG (1) SG11201704829QA (https=)
WO (1) WO2016109649A1 (https=)
ZA (1) ZA201704327B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016109649A1 (en) 2014-12-30 2016-07-07 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
WO2018132791A1 (en) * 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
WO2006116716A2 (en) 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
KR101286870B1 (ko) * 2009-11-30 2013-07-16 (주)아모레퍼시픽 황기 추출물을 포함하는 대사 촉진 조성물
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
WO2013116691A1 (en) 2012-02-02 2013-08-08 The Washington University Methods for improving muscle strength
KR101626526B1 (ko) 2014-10-30 2016-06-02 경북대학교 산학협력단 hRheb를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물
WO2016109649A1 (en) 2014-12-30 2016-07-07 University Of Iowa Research Foundation Methods and compositions for treating brain diseases

Also Published As

Publication number Publication date
US11612641B2 (en) 2023-03-28
EP3240577A1 (en) 2017-11-08
EP3240577A4 (en) 2018-07-25
CN107405414A (zh) 2017-11-28
HK1245127A1 (en) 2018-08-24
CA2971687A1 (en) 2016-07-07
US20180000907A1 (en) 2018-01-04
WO2016109649A1 (en) 2016-07-07
NZ733014A (en) 2024-05-31
ZA201704327B (en) 2025-02-26
JP6782701B2 (ja) 2020-11-11
CA2971687C (en) 2024-05-28
EP3240577B1 (en) 2023-07-05
JP2018502112A (ja) 2018-01-25
KR20170098931A (ko) 2017-08-30
ES2962439T3 (es) 2024-03-19
BR112017013674A2 (pt) 2018-02-06
KR102618947B1 (ko) 2023-12-27
AU2015374043B2 (en) 2021-05-13
AU2015374043A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
IL265497B (en) Methods for treating eye diseases
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL246791A0 (en) Compositions and methods for treating eye diseases
ZA201705673B (en) Methods for treating skin
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
ZA201601024B (en) Methods and compositions for treating brain diseases
IL253244B1 (en) Methods for treating retinal diseases
SG11201705093UA (en) Composition for treating il-6-related diseases
IL251759A0 (en) Preparations and methods for treating insomnia
IL293712A (en) Methods for treating mild brain injury
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
SG11201704829QA (en) Methods and compositions for treating brain diseases
IL253847A0 (en) Methods of treating diseases
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
IL252904A0 (en) Methods and factors for treating diseases
IL250658A0 (en) Methods for treating mild brain injury
IL250114B (en) Methods and compositions for the treatment of HIV-related diseases
IL252707B (en) Compositions and methods for treating diseases
GB201521083D0 (en) Compositions for treatment and methods thereof
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes